QL-335

N/A

Report date: 2026/03/19 17:14:58

Base Information

Drug NameQL-335
Drug Alias NameQL-335QL335
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionLymphocyte antigen 6 complex locus protein G6d inhibitorsT cell surface glycoprotein CD3 inhibitors
TargetsLymphocyte antigen 6 complex locus protein G6dT cell surface glycoprotein CD3
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesQlsf Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesQlsf Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A